Personalizing the Use of Pembrolizumab for Patients Who Have a Strong Response in Early Triple Negative Breast Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
OPT-PEMBRO trial is a pragmatic, multicentre, international, prospective, non-inferiority, two-arms, randomised (1:1), open-label, Phase III clinical study. The main goal of this research is to determine if patients with triple-negative breast cancer, who experience a complete response after neoadjuvant treatment, have the same chance of avoiding cancer recurrence whether they stop pembrolizumab or continue taking it for an additional 6 months. This research will also take into account patients tolerance to treatment and quality of life.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Podpisana zgoda pacjenta na uczestnictwo w badaniu
- •Wiek co najmniej 18 lat
- •Dobry stan ogólny pacjenta (zdolność do codziennych czynności)
- •Rak piersi w stadium II-III potwierdzone badaniem histologicznym
- •Rak trójujemny (brak receptorów estrogenowych, progesteronowych i HER2)
- •Wcześniejsze leczenie chemioterapią i lekiem pembrolizumab (minimum 6 cykli przed operacją)
- •Brak pozostałości nowotworu w piersi lub węzłach chłonnych po leczeniu
- •Wystarczające wyniki badań krwi i funkcji narządów wewnętrznych
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 23, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (2)
Cliniques Universitaires Saint Luc Brussels
Brussels, Belgium
Institut Gustave Roussy
Villejuif, France
Trial contact
Sonia Mardinian
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/1/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.